Park, J. C., Licitra, L. F., Shreenivas, A. V., Su, Y., Nair, S. M., Teague, A. S., Adkins, D., Sheth, S., Kim, H. R., Martinalbo, J., Durana, Y. D. D., Senne, L., Kalabus, J., Garcia, J., Zandberg, D. P. (2025). HexAgon-HN: Phase 2/3, randomized study of the hexavalent OX40 agonist INBRX-106 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for recurrent/metastatic head and neck cancer with a PD-L1 combined positive score of ≥20.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps6109